Purpose: We report a novel finding on spectral domain optical coherence tomography in patients with choroideremia, which we describe as scleral pits (SCPs).
C
horoideremia is an X-linked (Xq21) recessive disease caused by mutations in the CHM gene, which encodes the Rab escort protein-1 (REP1). [1] [2] [3] [4] It is a relatively rare disease with a prevalence of 1:50,000. 5 Early clinical manifestations include a loss of peripheral and night vision, which progress to tunnel vision and eventual loss of central vision in later stages of the disease. 6 During childhood, the fundus characteristics may manifest as peripapillary atrophy and widespread pigment clumping at the level of the retinal pigment epithelium (RPE), which then evolve later into lobular atrophic areas involving the retina, RPE, and the choriocapillaris. 7 These areas can coalesce, resulting in a pale fundus from the revelation of underlying scleral tissue covered by preserved large choroidal vessels. [8] [9] [10] Although the disease primarily manifests in men, carrier women may also be affected, but usually they demonstrate patchy and less severe degeneration because of random lyonization of the X-chromosome. 11, 12 The order of cell death in choroideremia is unclear. Most reports show that RPE is primarily affected with secondary degeneration of the photoreceptors and choriocapillaris; however, other studies alternatively suggest that photoreceptors degenerate first or that both RPE and photoreceptors degenerate independently with secondary damage to choroid. [13] [14] [15] [16] [17] Multimodal imaging using optical coherence tomography (OCT) and other imaging techniques in choroideremia are limited because of rarity of the disease. Previous reports have demonstrated changes such as choroidal neovascularization, cystoid macular edema, epiretinal membranes, outer retinal tubulations, intralaminar bridges, macular hole formation, and macular holes complicated by retinal detachment. 15, [18] [19] [20] [21] [22] [23] The OCT study by Jacobson et al 15 showed that retinal remodeling in choroideremia starts with retinal thickening, followed by photoreceptor degeneration, RPE depigmentation, and then retinal thinning with neuronal cell death and loss of laminar architecture. 14 A recent study using en face OCT and OCT angiography showed that at different stages, RPE and choriocapillaris loss exceeded photoreceptor loss. 24 In this study, we report a novel OCT finding in choroideremia that is correlated with disease course and may play a role in presurgical considerations for gene-and cell-based therapies.
Methods
The study was performed in accordance with the tenets of the Declarations of Helsinki, and the study protocol was approved by each institution's research ethical committee. Informed consent was obtained from all subjects. Clinically confirmed cases of choroideremia were reviewed from our pool of patients seen at Casey Eye Institute (Portland, OR) and Department of Ophthalmology, Rigshospitalet, Glostrup (Copenhagen, Denmark). Inclusion criteria were male subjects aged 18 years or older, having a clinical phenotype with or without genetic diagnosis of choroideremia, and having a disease clinically visible within the macular region. The exclusion criteria were history of amblyopia in either eye, concurrent retinal disease of other etiology, or presence of motion or media-opacity artifact in the OCT image.
All patients had detailed clinical examination including best-corrected visual acuity, intraocular pressure, and refraction. Snellen chart or Early Treatment of Diabetic Retinopathy Study chart was used for visual acuity testing, which were converted to logarithm of the minimum angle of resolution visual acuities for statistical purposes. Manifest refraction was documented for all eyes except in case of pseudophakia or poor visual acuity. After dilation, patients underwent imaging with spectral domain OCT, infrared reflectance, fluorescein angiography, and indocyanine green angiography using the SPEC-TRALIS (wavelength: 870 nm; Heidelberg Engineering Co, Heidelberg, Germany), 30°or 50°color fundus photograph using the FF450 (Carl Zeiss Meditec, Dublin, CA), and widefield fundus autofluorescence (FAF) using the Optos 200Tx confocal scanning laser ophthalmoscope (Optos PLC, Marlborough, MA). The OCT was obtained in high-resolution mode with 97 b scans centered on the fovea. Because our cohort consisted of patients with a wide age range at two different clinical centers, it was not possible to perform an identical scanning protocol on all patients.
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Reprint requests: Paul Yang, MD, PhD, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Boulevard, Portland, OR 97239; e-mail: yangp@ohsu.edu without the involvement of Bruch membrane, RPE, and retina. The number of SCP was counted for each eye within the area of the OCT volume scan, which consists of a 20°· 20°area or 20°· 15°area centered on the fovea. To fully visualize the extent of certain SCP, enhanced-depth imaging OCT was additionally performed in five subjects. The SCP identified on OCT was further characterized on infrared reflectance and FAF. All data collected from the right and left eyes from each patient were highly correlated (data not shown), and thus, the averaged values of both eyes were used to represent each patient. Unpaired two-tailed t-tests with Welch correction were used for statistical analysis.
Results
Of 36 patients with choroideremia included in the study, 19 had SCP in at least one eye (53%). Of those, 13 had SCP in both eyes. Genetic testing demonstrating a mutation in CHM was available for 26 patients (16 with SCP vs. 10 without SCP; Table 1 ). Regardless of genetic confirmation, all patients had clinical findings and a family history consistent with choroideremia. Two eyes were excluded: one because of presence of a choroidal neovascular membrane and the other because of a technical error. Scleral pits were localized to areas of advanced chorioretinal degeneration but never involved the foveola. Three types of SCP were observed (Figure 1) . Type 1 had intact Bruch membrane, residual RPE, and retina. Type 2 had a break in Bruch membrane and RPE with or without focal retinal excavation, whereas Type 3 had focal full-thickness retinal loss. Type 1 SCP was difficult to detect on fundus examination or with infrared reflectance or FAF imaging, and was only visible on OCT. Type 2 and 3 SCPs were seen on fundus examination as focal round depressions that were hyporeflective on infrared reflectance and hypoautofluorescent on FAF, which was indicative of the RPE defect. Enhanced-depth imaging OCT performed in five subjects showed that SCP extended deeply into the outer sclera. Fundus angiography was performed for one patient (No. P10) with Type 3 SCP, wherein the cavitation seemed to cause an interruption in a retinal vessel. Fluorescein angiography revealed that the retinal vessel filled normally but had a circuitous route following a path around the edge of the SCP lesion (Figure 2 ), whereas indocyanine green angiography showed no discrete cyanescence that correlated with the SCP.
Patients with SCP were significantly older (51 ± 2 vs. 33 ± 4 years; P , 0.05) and had poorer acuity (20/160 vs. 20/30 or 0.9 ± 0.2 vs. 0.2 ± 0.06 logarithm of the minimum angle of resolution; P , 0.05) compared with patients without SCP (Figure 3 ). Patients with SCP had a greater myopic refractive error compared with patients without SCP (22.6 ± 0.5 vs. 20.3 ± 0.5D; P , 0.05). However, there was no significant correlation between the number of SCPs with age, best-corrected visual acuity, or refraction. There was no significant difference in intraocular pressure between the group with SCP and the group without SCP. This study was not powered to determine correlations based on types of SCP because of the low numbers of subjects and presence of more than one type in some eyes.
Discussion
We have characterized SCPs as a novel OCT finding in patients with choroideremia, which are discrete fovea-sparing lesions that involve the macula, and appear as dramatic structural defects of the sclera, and to varying degrees, Bruch membrane, RPE, and retina. The spectrum of SCP in choroideremia seems phenotypically different from those typically found in pathologic myopia that is characterized as a posterior thinning and outpouching of the scleral on OCT. 25, 26 However, some SCP in choroideremia resemble the peripapillary lesions in pathologic myopia as described by Ohno-Matsui et al. 27 In addition, Ohno-Matsui et al also showed that short posterior ciliary arteries penetrate the eye at the sites of SCP, which is similar to our findings in choroideremia. Although the patients with choroideremia in our cohort were not high myopes, the patients with SCP were significantly more myopic than those without SCP, suggesting that moderate levels of myopia may exacerbate choroidal thinning and contribute to risk of developing SCP in choroideremia. Patients with SCP were also significantly older and had significantly poorer visual acuity than those without SCP, which suggests that SCP is a phenomenon that develops late in the disease course of choroideremia. Previous reports showed that choroideremia becomes more asymmetric in older patients, 28 which may explain the unilaterality of SCP in about a third of our patients.
Previous histological reports of choroideremia have demonstrated degeneration in the retina, RPE, Patients with SCPs were significantly older (A), and had worse best-corrected visual acuity (B) than patients without SCPs. SCP, scleral pit; BCVA, best-corrected visual acuity; asterisk, P , 0.05. and choriocaplliaris; 12,13 however, there are no known histological descriptions that correspond with SCP as described in this study. Without histopathology, it is unknown whether SCP are still lined with vascular endothelial cells, and whether Type 3 SCP are indeed full-thickness perforations of the globe or whether a thin hyporeflective membrane between the two spaces remains. Based on the results of angiography and similarities to peripapillary SCP in high myopia, the etiology of SCP in choroideremia is most likely due to the abnormal juxtaposition of penetrating short posterior ciliary arteries with the retina as a result of severe choroidal atrophy.
It is unknown whether SCP is specific to choroideremia or may also be found in other choroidal dystrophies. In addition, this study was also limited by the retrospective nature and relatively small sample size; however, choroideremia is a rare disease. Studies in larger groups of patients with choroideremia will be necessary to determine whether the different types of SCP identified in this study are correlated with different CHM mutations.
Scleral pits are, to the best of our knowledge, a novel OCT finding in choroideremia, especially in patients with reduced visual acuity and advanced disease. It is unknown whether vitrectomy or subretinal injection may disrupt the residual Bruch membrane and RPE layer of an SCP, which would hasten drainage and reduce anatomical sequestration of subretinal-delivered therapeutic agents, especially because it pertains to retinal gene-and cell-based therapies. If so, treatment efficacy may be affected, not only by limiting retention of the therapeutic agent, but also by compromising subretinal space-associated immune tolerance from potential exposure of the vector capsid or stem-cell antigens to choroidal dendritic cells and lymphatics. These potential issues may be especially problematic for Type 3 SCP, even if a thin membrane remains that cannot not be visualized by OCT separating the two compartments. Additional studies will be needed to determine whether areas with numerous SCP should be avoided in the ongoing retinal gene therapy clinical trials for choroideremia.
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